The change and clinic significance of MMP-9 and TIMP-1 in acute ischemic stroke

Objective To study the change of serum matrix metalloproteinase 9( MMP-9) and tissue inhibitor of matrix metalloproteinase 1( TIMP-1) in acute ischemic stroke patients( AIS),and analyse the relationship with disease prognosis. Methods 226 AIS patients were enrolled in the investigation. Based on the MESS,patients were divided into different groups according to the levels of severity and prognosis. And 164 physically healthy subjects were selected as controls. The concentration of serum MMP-9,TIMP-1,and MMP-9 / TIMP-1 were determined in all cases after being attacked within 24 hour,day3,day14 and day28 respectively. Results( 1) Serum contents of MMP-9,TIMP-1,and MMP-9 / TIMP-1 in AIS in different stages had significant difference. Serum contents of MMP-9,TIMP-1,and MMP-9 / TIMP-1 in AIS were remarkably higher than controls[( 377. 58 ± 32. 77) ng / ml,( 302. 29 ± 42. 25) ng / ml,( 1. 25 ± 0. 17) and( 67. 38 ± 10. 46) ng / ml,( 100. 68 ± 34. 21) ng / ml,( 0. 67 ± 0. 11),P 0. 01].( 2) Serum contents of MMP-9,TIMP-1,and MMP-9 / TIMP-1 among the light,medium and heavy cases after being attacked in 24hour had significant difference.( 3) Serum contents of MMP-9,TIMP-1,and MMP-9 / TIMP-1 in basically curable cases and remarkably improved cases after being attacked in day28 were remarkably lower than unchanged ones.( 4) The levels of hs-CRP、glucose and LDL-C were correlated with the levels of MMP-9 in AIS. Conclusions The change of serum MMP-9,TIMP-1 and imbalance of MMP-9 / TIMP-1 are significant bioindicators to evaluate the level of severity and prognosis of AIS.